Edwards Lifesciences Corporation EW
- Market cap
- $49.4B
- P/E
- 49.6×
Follow EW
Edwards Lifesciences Corporation (EW) EV/EBITDA
As of 25 September 2026, Edwards Lifesciences Corporation (EW) trades at a EV/EBITDA of 28.6×. Over the past ten years it has ranged from 19.6× (December 2016) to 62.2× (June 2021); the current reading is higher than 44% of that period. That is above the Medical Devices industry median of 11.8× and above the Healthcare sector median of 10.4×.
EV/EBITDA, daily
Annual
| Period | EV/EBITDA | Change |
|---|---|---|
| FY2025 | 32.6× | 22.10% |
| FY2024 | 26.7× | (13.56%) |
| FY2023 | 30.8× | 11.32% |
| FY2022 | 27.7× | (36.72%) |
| FY2021 | 43.8× | (21.47%) |
| FY2020 | 55.8× | 44.51% |
| FY2019 | 38.6× | (1.34%) |
| FY2018 | 39.1× | 97.17% |
| FY2017 | 19.8× | (14.78%) |
| FY2016 | 23.3× | 0.57% |
Quarterly
| Period | EV/EBITDA | Change |
|---|---|---|
| Jun 2026 | 30.0× | 4.56% |
| Mar 2026 | 28.7× | (11.72%) |
| Dec 2025 | 32.6× | 21.90% |
| Sep 2025 | 26.7× | 1.93% |
| 42 more quarters | Free account |
Against its own ten years
EV/EBITDA against peers
| Company | EV/EBITDA |
|---|---|
| PHG Koninklijke Philips N.V. compare | 8.6× |
| ZBH Zimmer Biomet Holdings, Inc. compare | 10.6× |
| GEHC GE HealthCare Technologies Inc. compare | 11.9× |
| STE STERIS plc compare | 13.4× |
| MDT Medtronic PLC compare | 13.7× |
| BSX Boston Scientific Corporation compare | 13.8× |
| SYK Stryker Corporation compare | 17.2× |
| DXCM DexCom, Inc. compare | 23.2× |
| EW Edwards Lifesciences Corporation | 28.6× |
| Medical Devices industry median | 11.8× |
| Healthcare sector median | 10.4× |
| Market median | 11.0× |
What EV/EBITDA is
Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)
More on EW
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement